Tracking minimal residual disease in cancer using advanced blood tests
Comprehensive minimal residual disease tracking in cancer
This study is looking at new ways to find tiny amounts of cancer cells in the blood, which could help patients get better early detection, track how well their treatment is working, and adjust their care if needed.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10994176 on NIH RePORTER |
What this research studies
This research focuses on improving the detection of minimal residual disease (MRD) in cancer patients through innovative liquid biopsy techniques. By analyzing circulating tumor DNA (ctDNA) in the blood, the study aims to enhance early cancer detection, monitor treatment effectiveness, and identify potential drug resistance. The research will explore advanced methods to detect ctDNA in cancers that are traditionally difficult to assess, potentially leading to better patient outcomes. Patients may benefit from more accurate monitoring of their cancer status and tailored treatment plans based on their individual disease dynamics.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with various types of cancer, particularly those with gliomas, gastric, and renal cancers, who may benefit from enhanced ctDNA detection methods.
Not a fit: Patients with cancers that are already well-managed with existing monitoring techniques may not receive additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective monitoring and treatment strategies for cancer patients, improving their chances of long-term survival.
How similar studies have performed: Previous research has shown promising results with similar liquid biopsy techniques, indicating potential for significant advancements in cancer monitoring.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Makrigiorgos, G. Mike — Dana-Farber Cancer Inst
- Study coordinator: Makrigiorgos, G. Mike
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.